Specialty chemicals manufacturer Epigral is targeting revenue of Rs. 50 bn by FY31, supported by production capacity expansions in chlorinated polyvinyl chloride (CPVC) resin and epichlorohydrin (ECH), Chairman and Managing Director Maulik Patel said. The company expects revenue to reach Rs. 29 bn in the current financial year, compared with Rs. 25-25.3 bn reported for FY26.

Epigral is doubling its CPVC resin capacity from 75,000 t to 150,000 t annually and its ECH capacity from 50,000 t to 100,000 t. Both projects are located at the company’s existing units in Dahej, Gujarat, and are expected to be commissioned within the next few months.

The expansion phase involves capital expenditure of Rs. 6.5 bn, which has been funded entirely through internal accruals. The projects are expected to make a partial contribution to revenue during the current financial year and a more meaningful contribution from the next financial year as the additional capacity is utilised.

Epigral entered the ECH and CPVC resin businesses in 2022 after deciding to focus on import-substitution products. The company produces ECH using a renewable glycerine-based process rather than the crude-oil-based propylene route commonly used in Western markets. It has also established itself as India’s largest CPVC resin producer and aims to become the world’s largest manufacturer in the category after the capacity expansion.

The company has acquired additional land near its Dahej facility for a new chemistry line and is finalising a technology partner. The project is expected to be placed before the board in another quarter and will target a product for which about 90 per cent of Indian demand is currently met through imports. Patel did not disclose the planned capital expenditure but said it would exceed Rs. 10 bn.